EGFR and non-small cell lung carcinoma: In a multinational, multicenter, open-label, phase III trial, 1125 patients with advanced NSCLC were randomly assigned to receive cisplatin alone and cisplatin plus cetuximab (an EGFR tyrosine kinase inhibitor).